MarketPeel
Insider Trading Intelligence
VV

Vincent Vultaggio

ZNTL
PRINCIPAL ACCOUNTING OFFICER · ZENTALIS PHARMACEUTICALS, INC. · CIK 0002018766
FILING MIX · LIFETIME30%/70%
BUYS
3
SELLS
7
TOTAL VALUE
$115.0K
COMPANIES
1
ACTIVE SINCE
Oct 2024
HOLDINGS NOW
146,506
AVG SELL PX
$2.42
TRADE KIND
SHOWING 10 / 10
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
7 backtested trades · 8 horizons · 17 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Vincent Vultaggio, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d7+71.43%-1.61%-0.25%-1.36%-0.33%
14d7+42.86%+3.54%-0.14%+3.68%+1.43%
30d7+14.29%+6.39%-1.97%+8.36%+11.24%
60d7+42.86%+47.13%-4.12%+51.26%+10.47%
90d7+28.57%+41.88%+3.37%+38.51%+56.11%
180d7(5 pending)+100.00%-40.02%+1.74%-41.75%-41.75%
1y7(5 pending)+50.00%+7.82%+16.62%-8.80%-8.80%
2y7(7 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ZNTL · 146,506 shares · as of Feb 10, 2026
048,11096,221144,331192,44120252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2024
2025
2025
2025
2025
2026
FLOW · 3 buys / 7 sellsCOVERAGE · 6 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
6,894$2.42$16.7K146,506Feb 10, 2026Feb 10, 2026View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
3,379$2.39$8.1K153,400Feb 9, 2026Feb 10, 2026View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
29,951$2.43$72.8K156,779Feb 6, 2026Feb 10, 2026View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
556$2.52$1.4K186,730Feb 3, 2026Feb 4, 2026View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
2,540$2.55$6.5K187,286Feb 2, 2026Feb 4, 2026View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
100,000100,000Jan 8, 2026Jan 9, 2026View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
158,586192,441Feb 3, 2025Feb 5, 2025View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
35,63335,633Feb 3, 2025Feb 5, 2025View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE
PAO and Interim PFO
2,615$1.71$4.5K189,826Feb 3, 2025Feb 5, 2025View →
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
1,603$3.18$5.1K33,855Oct 4, 2024Oct 4, 2024View →
Other insiders · ZNTL
Loading peer insiders…
About this filer
CIK 0002018766
ROLE
Principal Accounting Officer
PRIMARY
ZNTL
COMPANIES
1
ACTIVE SINCE
Oct 2024
MARKETPEEL · /INSIDER/0002018766DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback